EcoDrugPlus

Prostaglandin E2 Receptor Ep1 Subtype-Like

Ensembl ID : ENSSPAG00000018233
Gene Symbol: LOC103358683
3 Cross references
164 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSSPAG00000009705
Gene Symbol: LOC103360740
3 Cross references
202 Possible Orthologues:

Prostaglandin E2 Receptor Ep4 Subtype-Like

Ensembl ID : ENSSPAG00000008566
Gene Symbol: LOC103371850
3 Cross references
200 Possible Orthologues:

Prostaglandin F Receptor

Ensembl ID : ENSSPAG00000018830
Gene Symbol: PTGFR
3 Cross references
195 Possible Orthologues:

Prostaglandin I2 Receptor

Ensembl ID : ENSSPAG00000019403
Gene Symbol: PTGIR
3 Cross references
187 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSSPAG00000011460
Gene Symbol: PTGS1
3 Cross references
212 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 1

Ensembl ID : ENSSPAG00000015087
Gene Symbol: PTGS1
3 Cross references
182 Possible Orthologues:

Prostaglandin-Endoperoxide Synthase 2

Ensembl ID : ENSSPAG00000015504
Gene Symbol: PTGS2
3 Cross references
214 Possible Orthologues:

Proteasomal Ubiquitin Receptor Adrm1-Like

Ensembl ID : ENSSPAG00000000240
Gene Symbol: LOC103356008
3 Cross references
194 Possible Orthologues:

Proteasome 20s Subunit Alpha 1

Ensembl ID : ENSSPAG00000021415
Gene Symbol: PSMA1
3 Cross references
270 Possible Orthologues:

Proteasome 20s Subunit Alpha 2

Ensembl ID : ENSSPAG00000018079
Gene Symbol: PSMA2
3 Cross references
269 Possible Orthologues:

Proteasome 20s Subunit Alpha 3

Ensembl ID : ENSSPAG00000004606
Gene Symbol: PSMA3
3 Cross references
238 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).